In biotech, the biggest delays and costs don’t come from science but from communication breakdowns between technical and ...

The company recently wowed investors with clinical trial results.

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

They have at least one thing in common: An exciting pipeline.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.